C4 Therapeutics (CCCC) EBT Margin (2019 - 2025)
Historic EBT Margin for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 286.43%.
- C4 Therapeutics' EBT Margin fell 1258600.0% to 286.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 395.08%, marking a year-over-year decrease of 825600.0%. This contributed to the annual value of 295.6% for FY2024, which is 3365700.0% up from last year.
- Latest data reveals that C4 Therapeutics reported EBT Margin of 286.43% as of Q3 2025, which was down 1258600.0% from 402.6% recorded in Q2 2025.
- Over the past 5 years, C4 Therapeutics' EBT Margin peaked at 77.99% during Q4 2021, and registered a low of 1348.42% during Q2 2023.
- In the last 5 years, C4 Therapeutics' EBT Margin had a median value of 363.66% in 2025 and averaged 515.29%.
- As far as peak fluctuations go, C4 Therapeutics' EBT Margin plummeted by -12249200bps in 2022, and later soared by 12008600bps in 2024.
- Over the past 5 years, C4 Therapeutics' EBT Margin (Quarter) stood at 77.99% in 2021, then plummeted by -1571bps to 1302.91% in 2022, then increased by 19bps to 1057.25% in 2023, then surged by 37bps to 665.29% in 2024, then soared by 57bps to 286.43% in 2025.
- Its EBT Margin stands at 286.43% for Q3 2025, versus 402.6% for Q2 2025 and 363.66% for Q1 2025.